Neurent Medical Announces Limited Market Release of NEUROMARK® System...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: March 26, 2023

ARGO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Argo B • DISH ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against DISH Network Corporatio • Build community with shared future, create better world • National University Receives 2023 Military Friendly® Gold Designation • SOTERA HEALTH 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Los • HYZON MOTORS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers • SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Stanley Black & Decker, Inc. with Losses of $100,000 t • Early Education Leadership Conference in Hershey Brings Together Hundreds of Child Advocates • Statement from the Chief Public Health Officer of Canada on World TB Day • ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting • SOTERA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sote • SBNY LOSS ALERT: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Signature Bank Investors to Secure Counsel Before Important D • GINKGO BIOWORKS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Office • Here Comes Bunnysaurus Rex Hopping Down the Dinosaur Trail • Atlanta Housing, Residents Celebrate 102nd Birthday of Clara "Mama" Bridges • SAMARITAN'S PURSE RUSHING HELP TO FAMILIES IMPACTED BY DEADLY TORNADOES IN MISSISSIPPI • Philadelphia Works Names First Female Chief Operating Officer • Jennifer S. Wilkov Finalizes Lineup for the 2023 April Speak Up Women Conference • NATIONAL VISION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Aga • Korelya Capital Invests in Weo, Bringing Total Funds Raised to $15M, and Leads Launch of its Series A Financing Round

Neurent Medical Announces Limited Market Release of NEUROMARK® System to Treat Chronic Rhinitis

GALWAY, Ireland , February 03 /Businesswire/ - Neurent Medical, a company pioneering innovative non-surgical interventions to treat chronic inflammatory sino-nasal diseases, today announced its NEUROMARK^® Rhinitis Neurolysis Therapy (RNT) is now commercially available in limited U.S. markets. Commercialization comes as the American Medical Association (AMA) issued a new Category I Current Procedural Terminology (CPT^®) code for posterior nasal nerve ablation (PNN) procedures, which includes NEUROMARK, to treat chronic rhinitis. The code will go into effect in January 2024. Furthermore, the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) endorses this procedure.

Approximately one in four Americans suffer from chronic rhinitis¹, which can result in irritating symptoms including rhinorrhea (runny nose), persistent congestion, swelling of the mucosal membrane in the nose, and sneezing and nasal itching caused by inflammation. NEUROMARK’s unique device and intelligent technology platform enable Otolaryngologists to treat chronic rhinitis patients with precision and control and enhance the patient experience from treatment through recovery.

“Our goal is to provide an easy-to-operate, smart treatment that provides clinicians with more precise control and confidence, and patients with a safe, comfortable experience,” said Brian Shields, CEO of Neurent Medical. “The new CPT code underscores the value of this technology as we further grow our commercial presence in the U.S. and work to make NEUROMARK more accessible to the millions of patients living with chronic rhinitis today.”

NEUROMARK is designed to gently apply controlled low-power radio frequency (RF) energy to target regions of the nasal cavity, disrupting the parasympathetic nerve signals that can trigger an inflammatory response. This unique system offers ENTs a novel and unique leaflet design to help deliver precision neurolysis of posterior nasal nerves, with the intelligence and flexibility to comfortably accommodate a range of anatomies.

The recent endorsement² of PNN by the AAO-HNS, a specialty society representing almost 12,000 ENT surgeons, further validates Neurent Medical’s long-term future in the treatment of chronic rhinitis.

About Neurent Medical

Neurent Medical is pioneering innovative treatments for chronic inflammatory sino-nasal diseases by targeting and safely disrupting hyperactive autonomic nerves that drive underlying inflammation. Its proprietary NEUROMARK^® technology with a unique design and advanced algorithmic control, physicians can precisely target and safely disrupt multiple underlying nerve branches in a single procedure to alleviate Chronic Rhinitis symptoms and improve patient quality of life. The venture capital-backed company is headquartered in Galway, Ireland. For more information visit www.neurentmedical.com.

__________________

1 Settipane RA, Charnock DR. Epidemiology of rhinitis: allergic and nonallergic. Clin Allergy Immunol. 2007;19:23-34. PMID: 17153005.

2 Position Statement: PNN Ablation for the Treatment of Chronic Rhinitis. American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS). (2023, January 17).